CEO Michael Gilman said Arrakis faced an “unbelievable amount of skepticism” when it got started around 2017. In an interview with the Business Journal, Gilman explains how the company charted ...
"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic dystrophy type 1 (DM1), with the drug reversing the prolonged muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback